However, excessive or incorrect doses of folate can hinder fibrosis in NAFLD patients: during NAFLD fibrogenesis, HSCs undergo folate-mitochondrial metabolic switches activating the mitochondrial enzymes serine hydroxymethyltransferase 2 (SHMT2) and methylenetetrahydrofolate dehydrogenase 2 (MTHFD2), which are the bridge between mitochondrial folate metabolism and polyunsaturated FA metabolism [146]. Here, MTHFD2 is linked to metabolic dysfunction-associated steatotic liver disease.